Glutamine, a hypoglycemic agent that was studied to treat diabetes. Information about the current use of this compound is not available.

Guaietolin was used as an oral expectorant.

Ganglefene is a coronary vasodilator. This n-cholinoblocker was originally studied for its effects on coronary circulation in angina pectoris. Animal studies have also shown shortened recovery period of motor functions after ganglefene administration. One rodent study showed that modulation of the n-cholinergic system by ganglefene in the developing fetal brain leads to changes in the quantitative and qualitative characteristics of elements of sexual behavior in pubescent offspring.

NMS-P937 is a selective PLK1 inhibitor. It was developed by Nerviano Medical Sciences and tested in phase I clinical trials.

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.

Vintiamol was developed as a new form of vitamin B1. Information about the current use of this agent is not available.

Tropapride is dopamine D2 receptor antagonist, which potential high antipsychotic activity has been clearly shown in biochemical and pharmacological tests.

Basimglurant is a potent, selective, and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration, good brain penetration, and high in vivo potency. It has antidepressant properties that are corroborated by its functional magnetic imaging profile as well as anxiolytic-like and antinociceptive features. In electroencephalography recordings, basimglurant shows wake-promoting effects followed by increased delta power during subsequent non-rapid eye movement sleep. Basimglurant has favorable drug-like properties, a differentiated molecular mechanism of action, and antidepressant-like features that suggest the possibility of also addressing important comorbidities of MDD including anxiety and pain as well as daytime sleepiness and apathy or lethargy. Basimglurant is being under development by Roche for the treatment of treatment-resistant depression (as an adjunct). It is in phase II clinical trials for this indication.

Dapitant is an antagonist of neurokinin 1 (NK1) receptor, discovered by the French company Rhône-Poulenc Rorer. NK1 receptors are thought to mediate the neurogenic inflammatory effects of substance P. Dapitant demonstrated efficacy as an antimigraine agent in several animal models. However, in a global, double-blind, randomize, placebo-controlled trial in patients with migraine attacks with moderate or severe headache intensity, treatment with dapitant did not lead to an improvement in the intensity of headache, and the development of the drug was discontinued.

Nifuralide, a 5-nitrofuran derivative, is an antibacterial agent. It was used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.